# Ilika CEO and CFO discuss H1 performance, Goliath’s future and Cirtec’s role in Stereax (LON:IKA)

- Link: https://www.directorstalkinterviews.com/ilika-ceo-and-cfo-discuss-h1-performance-goliaths-future-and-cirtecs-role-in-stereax-lonika/4121140582
- Published: 2024-01-31T13:47:56+00:00
- Author: Amilia Stone

**[Ilika plc](https://www.directorstalkinterviews.com/company/ilika-plc/ika.l) (
[LON:IKA](https://www.directorstalkinterviews.com/company/ilika-plc/ika.l))** Chief
Executive Officer Graeme Purdy and Chief Financial Officer Jason Stewart caught 
up with DirectorsTalk for an exclusive interview to discuss first half performance,
what’s next for Goliath, how Cirtec fits into future Stereax plans, sector trends,
and a breakthrough year for the group.

**Q1: Just starting with you Jason, do you think Ilika’s first half performance 
was aligned with expectations?**

**A1**: Yes, I think we’ve performed very well in line if not slightly ahead, so
strong revenue especially if you look back year on year to the position at the half
year last year.

Really that’s underpinned on a revenue side by strong pull forward of our grant 
funding from the HISTORY project that we announced last year, with that being somewhat
more front-end loaded than we expected from the 2.8 million pounds that spread over
that two-year period. That really has underpinned the start of the good performance
with strong revenue.

From an operational side, we’ve done a good performance in terms of managing our
cost base and that has really come on the back of our Cirtec tech transfer for the
Stereax product. That has allowed us to manage our cost base around some of the 
more expensive clean room operations that we’ve now transferred over as part of 
that process.

Finally, with some of our other grant funded activity such as the SiSTEM project
where we’re working with Mpac on our assembly line, that’s allowed us to seek grant
funding to underpin some of our capital purchases.

Those three items together really come to support that strong cash position that
we’ve ended up with at the half year of £13.2 million, so all in all a good performance
in line if not slightly ahead of our expectations.

**Q2: Just turning to you Graeme, now that you’ve reached lithium-ion energy density
parity with your Goliath cells, what is next?**

**A2**: We’ve got two efforts that are running in parallel.

On the one hand we’ve got the productisation, if I can use that word, of the D4 
data point which then translates directly onto our P1 prototype, that’s a testing
programme to fully characterise the P1 cells. So, we’re making batches of identical
cells putting them through a structured testing programme and then releasing them
to our customers for evaluation and further testing.

In parallel, we’re also driving forward with our data point roadmap so going through
D4 all the way through to D8, eventually at the end of our current HISTORY grant
funded programme in Q1 of 2025. That in turn will become the basis for the P2 prototype
which is actually our minimum viable product and will form the basis for what the
automotive industry calls a-cells.

**Q3: Jason mentioned earlier Cirtec, could you explain for us though how your relationship
with Cirtec fits into your long-term plans for Stereax?**

**A3**: Cirtec have taken a 10-year technology transfer license to the Stereax products,
we have transferred our key equipment set across to the US and that is currently
being installed at their Lowell facility in Massachusetts.

That is being then qualified and made ready for production in the course of the 
next six months, and Cirtec are also actually take the lead in commercialising the
Stereax product. In fact, just last week, we were on a stand with them at the NANS
show, which is the North American Neurostimulation Show, over in San Diego and they’re
really helping drive forward the commercialisation and the commercial demand for
the Stereax products.

We expect to work with them to ramp up production and ramp up the commercialisation
of the products over the next few years.

**Q4: How are the sector trends and regulatory changes supporting your development
process, particularly with EVs?**

**A4**: I’m talking again about Goliath cells, there is a lot of regulatory-driven
transformation going on in the automotive sector. Clearly in Europe, we’ve got a
2035 deadline after which ICEs – Internal Combustion Engine – driven cars will no
longer be available.

So, EVs will dominate the new car market, and clearly the automotive companies are
preparing for that and so that regulation is important for driving the pace of transformation.

**Q5: Do you think this could be a breakthrough year for Ilika either financially
or operationally?**

**A5**: Well, there’s lots to look forward to this year.

First of all, we’ll be building with the Cirtec efforts hand in hand with the Stereax
agreement ramp up, as we commission that equipment and ramp up the co-marketing 
activities that we’ve got there. So, we’re getting ready then to supply customers
and meet that commercial demand.

On the Goliath side of the business, as we move through those milestones and share
product with customers, we’ll be able to firm up some of those agreements and make
them increasingly commercial as the batteries demonstrate their potential.

Share on:
